Martyn E. Caplin
Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs.
Overview
Martyn Caplin (Royal Free Hospital, London) was principal investigator of CLARINET, the trial showing lanreotide markedly prolongs progression-free survival in non-functioning gastroenteropancreatic neuroendocrine tumours, establishing somatostatin analogues as antiproliferative therapy rather than only symptom control. He leads one of Europe's largest NET centres and has chaired the European Neuroendocrine Tumor Society.
| Title | Journal | Year |
|---|---|---|
| Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET) | NEJM | 2014 |
| Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Endocrine-Related Cancer | 2016 |
Pages like this
not linked directly; found by shared links- IdeaSSTR antagonist radioligands to increase tumour dose
- PersonJonathan R. Strosberg
Shares Somatostatin receptor 2, Neuroendocrine tumours and the tag neuroendocrine.
- PersonSimron Singh
Shares Somatostatin receptor 2, Neuroendocrine tumours and the tag neuroendocrine.
- CompanyPOINT Biopharma
- ProductSomatostatin analogues (octreotide, lanreotide)
Shares CLARINET, Somatostatin receptor 2, Neuroendocrine tumours.
- PersonJames C. Yao
Shares Neuroendocrine tumours and the tag neuroendocrine.
- TrialCOMPETE
- PersonEmily K. Bergsland